日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects

一项全面的QTc研究,旨在评估口服利扎替尼单独给药以及与利托那韦联合给药对健康受试者的影响。

Ucpinar, Sibel; Darpo, Borje; Neale, Ann; Nunn, Philip; Shu, Jin; Chu, Katherine A; Kavanagh, Marianne; Xue, Hongqi; Phiasivongsa, Pasit; Thomas, Dolca; Smith, Patrick F

Towards a better use of scientific advice for developers of advanced therapies

如何更好地利用科学建议来指导先进疗法的研发?

Tavridou, Anna; Rogers, Dolca; Bonelli, Milton; Schiel, Anja; Hidalgo-Simon, Ana

Clinical considerations for the development of biosimilars in oncology

肿瘤生物类似药研发的临床考量

Socinski, Mark A; Curigliano, Giuseppe; Jacobs, Ira; Gumbiner, Barry; MacDonald, Judith; Thomas, Dolca

Development of biosimilars in an era of oncologic drug shortages

在肿瘤药物短缺的时代,生物类似药的研发

Li, Edward; Subramanian, Janakiraman; Anderson, Scott; Thomas, Dolca; McKinley, Jason; Jacobs, Ira A

Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes

在合并糖尿病的肾移植受者中,贝拉西普与环孢素类免疫抑制剂的比较

Rostaing, Lionel; Neumayer, Hans H; Reyes-Acevedo, Rafael; Bresnahan, Barbara; Florman, Sander; Vitko, Stefan; Heifets, Michael; Xing, Jun; Thomas, Dolca; Vincenti, Flavio

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study

在肾移植受者中,从基于钙调神经磷酸酶抑制剂的治疗方案转换为基于贝拉西普的治疗方案:一项随机II期研究

Rostaing, Lionel; Massari, Pablo; Garcia, Valter Duro; Mancilla-Urrea, Eduardo; Nainan, Georgy; del Carmen Rial, Maria; Steinberg, Steven; Vincenti, Flavio; Shi, Rebecca; Di Russo, Greg; Thomas, Dolca; Grinyó, Josep

Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma

扁桃体 NK 细胞通过 IFN-γ 限制 Epstein-Barr 病毒对 B 细胞的转化

Till Strowig, Fabienne Brilot, Frida Arrey, Gwenola Bougras, Dolca Thomas, William A Muller, Christian Münz